Cancer · 2021 · 23 citations · 23 references
PharmacyPharmacologyPharmacotherapyCancer Drug Toxicity ManagementClinical PharmacologyOncology PharmacotherapyMyeloproliferative NeoplasmsTreatment Response MonitoringRefractory Myeloproliferative Neoplasms
BACKGROUND: After ruxolitinib discontinuation, the outcome of patients with myelofibrosis (MF) is poor with scarce therapeutic possibilities. METHODS: The authors performed a subanalysis of an observational, retrospective study (RUX-MF) that included 703 MF patients treated with ruxolitinib to investigate 1) the frequency and reasons for ruxolitinib rechallenge, 2) its therapeutic effects, and 3) its impact on overall survival. RESULTS: A total of 219 patients (31.2%) discontinued ruxolitinib for ≥14 days and survived for ≥30 days. In 60 patients (27.4%), ruxolitinib was rechallenged for ≥14 days (RUX-again patients), whereas 159 patients (72.6%) discontinued it permanently (RUX-stop patients). The baseline characteristics of the 2 cohorts were comparable, but discontinuation due to a lack/loss of spleen response was lower in RUX-again patients (P = .004). In comparison with the disease status at the first ruxolitinib stop, at its restart, there was a significant increase in patients with large splenomegaly (P < .001) and a high Total Symptom Score (TSS; P < .001). During the rechallenge, 44.6% and 48.3% of the patients had spleen and symptom improvements, respectively, with a significant increase in the number of patients with a TSS reduction (P = .01). Although the use of a ruxolitinib dose > 10 mg twice daily predicted better spleen (P = .05) and symptom improvements (P = .02), the reasons for/duration of ruxolitinib discontinuation and the use of other therapies before rechallenge were not associated with rechallenge efficacy. At 1 and 2 years, 33.3% and 48.3% of RUX-again patients, respectively, had permanently discontinued ruxolitinib. The median overall survival was 27.9 months, and it was significantly longer for RUX-again patients (P = .004). CONCLUSIONS: Ruxolitinib rechallenge was mainly used in intolerant patients; there were clinical improvements and a possible survival advantage in many cases, but there was a substantial rate of permanent discontinuation. Ruxolitinib rechallenge should be balanced against newer therapeutic possibilities.
23
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Srđan Verstovšek, Hagop M. Kantarjian, Ruben A. Mesa et al. · New England Journal of Medicine · 2010 · 1.2K citations · Full text
Medicine, Hematology, Pharmacology +13
Naseema Gangat, Domenica Caramazza, Rakhee Vaidya et al. · Journal of Clinical Oncology · 2010 · 1K citations · Full text
European consensus on grading bone marrow fibrosis and assessment of cellularity.
Jürgen Thiele, Hans Michael Kvasnicka, Fabio Facchetti et al. · PubMed · 2005 · 770 citations
Medicine, Pathology, Hematopathology +15
Robyn M. Emanuel, Amylou C. Dueck, Holly L. Geyer et al. · Journal of Clinical Oncology · 2012 · 458 citations · Full text
Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · Journal of Hematology & Oncology · 2017 · 427 citations · Full text